2 results
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.
Approved WMOCompleted
Analysis of the effects of the Twin-Pulse Life Support on on the systemic inflammatory response and the effect on microvascular blood flow in ocmparison to standard used Extracorporeal Circuit Device